137 related articles for article (PubMed ID: 36379869)
1. Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review.
Neuenschwander A; Lonati C; Antonelli L; Papachristofilou A; Cathomas R; Rothermundt C; Templeton AJ; Gulamhusein A; Fischer S; Gillessen S; Hermanns T; Lorch A; Mattei A; Fankhauser CD
Eur Urol Focus; 2023 May; 9(3):541-546. PubMed ID: 36379869
[TBL] [Abstract][Full Text] [Related]
2. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer.
Pearce SM; Golan S; Gorin MA; Luckenbaugh AN; Williams SB; Ward JF; Montgomery JS; Hafez KS; Weizer AZ; Pierorazio PM; Allaf ME; Eggener SE
Eur Urol; 2017 Mar; 71(3):476-482. PubMed ID: 27234998
[TBL] [Abstract][Full Text] [Related]
3. Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective.
Rassweiler JJ; Scheitlin W; Heidenreich A; Laguna MP; Janetschek G
Eur Urol; 2008 Nov; 54(5):1004-15. PubMed ID: 18722704
[TBL] [Abstract][Full Text] [Related]
4. Trans- and extraperitoneal retroperitoneal lymph node dissection (RPLND) in the treatment for nonseminomatous germ cell testicular tumors (NSGCT): a single Chinese center's retrospective analysis.
Tong S; Chen M; Zu X; Li Y; He W; Lei Y; Liu W; Qi L
Int Urol Nephrol; 2014 Feb; 46(2):363-9. PubMed ID: 23996573
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome of post-chemotherapy retroperitoneal lymph node dissection in metastatic nonseminomatous germ cell tumour: A systematic review.
Haarsma R; Blok JM; van Putten K; Meijer RP
Eur J Surg Oncol; 2020 Jun; 46(6):999-1005. PubMed ID: 32173176
[TBL] [Abstract][Full Text] [Related]
6. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
[TBL] [Abstract][Full Text] [Related]
7. National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy.
Labbate CV; Werntz RP; Galansky LB; Packiam VT; Eggener SE
Urol Oncol; 2020 Aug; 38(8):687.e13-687.e18. PubMed ID: 32305267
[TBL] [Abstract][Full Text] [Related]
8. Management of patients with clinical stage I nonseminomatous testicular germ cell tumours: active surveillance versus primary chemotherapy versus nerve sparing retroperitoneal lymphadenectomy.
Heidenreich A; Pfister D
Arch Esp Urol; 2012 Mar; 65(2):215-26. PubMed ID: 22414450
[TBL] [Abstract][Full Text] [Related]
9. Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours.
Flechtner HH; Fischer F; Albers P; Hartmann M; Siener R;
Eur Urol; 2016 Mar; 69(3):518-25. PubMed ID: 26620368
[TBL] [Abstract][Full Text] [Related]
10. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
[No Abstract] [Full Text] [Related]
11. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
12. Management of patients with low-stage nonseminomatous germ cell testicular cancer.
Stephenson AJ; Sheinfeld J
Curr Treat Options Oncol; 2005 Sep; 6(5):367-77. PubMed ID: 16107240
[TBL] [Abstract][Full Text] [Related]
13. Impact of age on clinicopathological outcomes and recurrence-free survival after the surgical management of nonseminomatous germ cell tumour.
Masterson TA; Carver BS; Abel EJ; Pettus JA; Bosl GJ; Sheinfeld J
BJU Int; 2012 Oct; 110(7):950-5. PubMed ID: 22394608
[TBL] [Abstract][Full Text] [Related]
14. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors.
Nelson JB; Chen RN; Bishoff JT; Oh WK; Kantoff PW; Donehower RC; Kavoussi LR
Urology; 1999 Dec; 54(6):1064-7. PubMed ID: 10604709
[TBL] [Abstract][Full Text] [Related]
15. Robot-assisted Laparoscopic Retroperitoneal Lymph Node Dissection for Testicular Cancer: Evolution of the Technique.
Stepanian S; Patel M; Porter J
Eur Urol; 2016 Oct; 70(4):661-667. PubMed ID: 27068395
[TBL] [Abstract][Full Text] [Related]
16. Laparoscopic and open retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testis tumors.
Abdel-Aziz KF; Anderson JK; Svatek R; Margulis V; Sagalowsky AI; Cadeddu JA
J Endourol; 2006 Sep; 20(9):627-31. PubMed ID: 16999613
[TBL] [Abstract][Full Text] [Related]
17. Primary Robot-assisted Retroperitoneal Lymph Node Dissection for Men with Nonseminomatous Germ Cell Tumor: Experience from a Multi-institutional Cohort.
Taylor J; Becher E; Wysock JS; Lenis AT; Litwin MS; Jipp J; Langenstroer P; Johnson S; Bjurlin MA; Tan HJ; Lane BR; Huang WC
Eur Urol Focus; 2021 Nov; 7(6):1403-1408. PubMed ID: 32682794
[TBL] [Abstract][Full Text] [Related]
18. Association of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer.
Patel HV; Srivastava A; Kim S; Patel HD; Pierorazio PM; Bagrodia A; Masterson TA; Ghodoussipour SB; Kim IY; Singer EA; Jang TL
J Urol; 2022 May; 207(5):1057-1066. PubMed ID: 34978466
[TBL] [Abstract][Full Text] [Related]
19. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
Al-Tourah AJ; Murray N; Coppin C; Kollmannsberger C; Man A; Chi KN
J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765
[TBL] [Abstract][Full Text] [Related]
20. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
Stephenson AJ; Bosl GJ; Motzer RJ; Kattan MW; Stasi J; Bajorin DF; Sheinfeld J
J Clin Oncol; 2005 Apr; 23(12):2781-8. PubMed ID: 15837993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
